After publishing a promising clinical update yesterday, Bio-Path Holdings Inc (NASDAQ: BPTH) saw incredible gains. Those gains are continuing today as the data proved to be overwhelmingly meaningful. Below, we’ll talk about:
- The clinical data and why it is leading to such excitement;
- what we’re seeing from BPTH stock as a result; and
- what we’ll be watching for ahead.
BPTH Stock Continues To Rocket On Clinical Data
As mentioned above, Bio-Path Holdings issued a clinical update yesterday, sending the stock rocketing. The update surrounded the company’s asset, BP1001; an asset currently under development for the treatment of acute myeloid leukemia (AML).
The data proved to be overwhelmingly positive in the interim analysis that was completed in April of 2018. At the time, data suggested that 47% of patients responded to treatment. Moreover, 4 out of 17 patients had achieved a complete response.
Yesterday, BPTH updated these results. Now, the treatment has reached an efficacy profile of 65%. Moreover, 5 patients have achieved complete response with one achieving a morphologic leukemia free state. Also, 6 patients achieved stable disease with two of them showing a greater than 50% reduction in bone marrow blasts.
Why This Is So Important
Unfortunately, AML is a very difficult-to-treat cancer with few FDA approved options for patients. The data in the study suggests that BP1001 provides meaningful results to patients.
Should the data continue to be positive, it would be a strong foundation of support for a New Drug Application with the FDA. Also, considering that AML patients currently have few options, the drug could be a blockbuster, driving impressive revenue for BPTH.
On the other hand, the strong data makes the company a good takeover target for big players in the oncology space. While there’s no insinuation that a takeover is in the works at the moment, the pharma giants likely have their eye on the company after yesterday’s release.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to jump into the market is that it’s important to follow the news. After all, the news opens the door to opportunity as it moves the market.
When it comes to Bio-Path Holdings, the news was overwhelmingly positive. Improved data suggests that the company may have a meaningful treatment for patients with few options. It also suggests that BP1001 could evolve to become an incredible revenue generator.
Considering this, it’s not surprising to see that the stock is running for the top in the market yet again today. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (9:46), BPTH is trading at $27.02 per share after a gain of $15.00 per share or 124.79% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on BPTH. In particular, we’re interested in following the story surrounding the company’s continued work to bring BP1001 to market. We’re also watching for potential takeover interest as we believe that the big players have a lot to gain with an acquisition here. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!